Skip to main content
Top

21-07-2018 | Systemic sclerosis | Review | Article

Pain and Its Management in Systemic Sclerosis

Journal: Current Treatment Options in Rheumatology

Authors: Erin L. Merz, PhD, MPH, Shervin Assassi, MD, MS, Vanessa L. Malcarne, PhD

Publisher: Springer International Publishing

Abstract

Purpose of review

Pain is one of the most common quality of life concerns in systemic sclerosis (SSc). This review summarizes the literature on risk factors and potential clinical assessment and treatment strategies.

Recent findings

SSc pain is associated with, but not defined by, disease parameters and severity. The extant literature suggests that psychosocial factors such as mental health are relevant to pain. Brief pain screenings can be followed by a more comprehensive assessment to help inform intervention strategies for affected patients. The literature on pain management is relatively small, but numerous studies and clinical practice recommendations suggest that there are multiple avenues for intervention. These include medical treatments, physical activity and rehabilitation programs, and psychotherapeutic techniques.

Summary

There are many promising approaches to SSc pain treatment. Future research should include systematic evaluation of treatments that have been proposed in SSc and/or have demonstrated efficacy in other chronic pain or rheumatic samples. Particular attention should be paid to treatments that include a non-pharmacological component and are more easily accessible for patients.
Literature
1.
Medsger TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin N Am. 2003;29(2):255–73.CrossRef
2.
Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165–70.CrossRefPubMed
3.
Borenstein D, Altman R, Bello A, et al. Report of the American College of Rheumatology Pain Management Task Force. Arthritis Care Res. 2010;62(5):590–9.CrossRef
4.
Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, et al. The impact of pain and symptoms of depression in scleroderma. Pain. 2002;95(3):267–75.CrossRefPubMed
5.
•• Schieir O, Thombs BD, Hudson M, Boivin JF, Steele R, Bernatsky S, et al. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. Arthritis Care Res. 2010;62(3):409–17. Presents prevalance and correlates of SSc pain in a large sample.
6.
Merz EL, Malcarne VL, Roesch SC, Nair DK, Salazar G, Assassi S, et al. Longitudinal patterns of pain in patients with diffuse and limited systemic sclerosis: integrating medical, psychological, and social characteristics. Qual Life Res. 2017;26(1):85–94.CrossRefPubMed
7.
Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, et al. Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology. 2006;45(10):1298–302.CrossRefPubMed
8.
Hudson M, Thombs BD, Steele R, Watterson R, Taillefer S, Baron M, et al. Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 2008;59(2):279–84.CrossRefPubMed
9.
Mura G, Bhat KM, Pisano A, Licci G, Carta M. Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Heal. 2012;8:30–5.CrossRef
10.
Milette K, Razykov I, Pope J, Hudson M, Motivala SJ, Baron M, et al. Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. Rheumatology. 2011;50(5):921–5.CrossRefPubMed
11.
•• Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology. 2018;57(2):370–81. Recent, large study describing correlates of SSc pain in a large sample.
12.
Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology. 2011;50(4):762–7.CrossRefPubMed
13.
Yacoub YI, Amine B, Bensabbah R, Hajjaj-Hassouni N. Assessment of fatigue and its relationships with disease-related parameters in patients with systemic sclerosis. Clin Rheumatol. 2012;31(4):655–60.CrossRefPubMed
14.
Poole JL, Anwar S, Mendelson C, Allaire S. Workplace barriers encountered by employed persons with systemic sclerosis. Work. 2016;55(4):923–9.CrossRefPubMed
15.
Sandqvist G, Scheja A, Hesselstrand R. Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis. Rheumatology. 2010;49(9):1739–46.CrossRefPubMed
16.
Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150:971–9.CrossRefPubMed
17.
Fava GA, Sonino N. The biopsychosocial model thirty years later. Psychother Psychosom. 2008;77(1):1–2.CrossRefPubMed
18.
Carreira PE. “Quality of pain” in systemic sclerosis. Rheumatology. 2006;45(10):1185–6.CrossRefPubMed
19.
Sousa-Neves J, Cerqueira M, Santos-Faria D, Afonso C, Teixeira F. Neuropathic pain in systemic sclerosis patients: a cross-sectional study. Reumatol Clínica. 2018; https://​doi.​org/​10.​1016/​J.​REUMA.​2017.​12.​010.
20.
Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol. 2007;34:359–67.PubMed
21.
Richards HL, Herrick AL, Griffin K, Gwilliam PDH, Loukes J, Fortune DG. Systemic sclerosis: patients’ perceptions of their condition. Arthritis Rheum. 2003;49(5):689–96.CrossRefPubMed
22.
Del Rosso A, Boldrini M, D’Agostino D, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum. 2004;51(3):475–81.CrossRefPubMed
23.
Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum. 2002;46(9):2410–20.CrossRefPubMed
24.
Franck-Larsson K, Graf W, Rönnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study. Eur J Gastroenterol Hepatol. 2009;21(2):176–82.CrossRefPubMed
25.
Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum. 2013;43(3):335–47.CrossRefPubMed
26.
Edwards RR, Cahalan C, Calahan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol. 2011;7(4):216–24.CrossRefPubMed
27.
Kwakkenbos L, van Lankveld WGJM, Vonk MC, Becker ES, van den Hoogen FHJ, van den Ende CHM. Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. J Psychosom Res. 2012;72:199–204.CrossRefPubMed
28.
Hyphantis TN, Tsifetaki N, Siafaka V, Voulgari PV, Pappa C, Bai M, et al. The impact of psychological functioning upon systemic sclerosis patients’ quality of life. Semin Arthritis Rheum. 2007;37(2):81–92.CrossRefPubMed
29.
• Merz EL, Malcarne VL, Assassi S, Nair DK, Graham TA, Yellman BP, et al. Biopsychosocial typologies of pain in a cohort of patients with systemic sclerosis. Arthritis Care Res. 2014;66(4):567–74. This study presents a comprehensive, biopsychosocial framework of SSc pain.
30.
Hansdottir I, Malcarne VL, Furst DE, Weisman MH, Clements PJ. Relationships of positive and negative affect to coping and functional outcomes in systemic sclerosis. Cognit Ther Res. 2004;28(5):593–610.CrossRef
31.
van Lankveld W, Teunissen H, Näring G, Vonk M, van den Hoogen F. Social support, disease-related cognitions and coping as predictors of depressed mood in systemic sclerosis. Cogn Ther Res. 2008;32(3):434–47.CrossRef
32.
Edwards RR, Goble L, Kwan A, Kudel I, McGuire L, Heinberg L, et al. Catastrophizing, pain, and social adjustment in scleroderma: relationships with educational level. Clin J Pain. 2006;22(7):639–46.CrossRefPubMed
33.
Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007;133(4):581–624.CrossRefPubMed
34.
•• Joint Commission. New and revised standards related to pain assessment and management. Off Newsl Jt Comm. 2017;37(7):3–4. Provides updated standards for pain assessment and treatment of pain for healthcare providers.
35.
El-Baalbaki G, Lober J, Hudson M, Baron M, Thongs BD, Canadian Scleroderma Research Group. Measuring pain in systemic sclerosis: comparison of the short-form McGill Pain Questionnaire versus a single-item measure of pain. J Rheumatol. 2011;38(12):2581–7.CrossRefPubMed
36.
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale. Arthritis Care Res. 2011;63(S11):S240–52.CrossRef
37.
• Pope J. Measures of systemic sclerosis (scleroderma). Arthritis Care Res. 2011;63(S11):S98–S111. Reviews the literature on evidence-based assessment tools for pain.
38.
Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;3:277–99.CrossRef
39.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.PubMed
40.
Nicholas MK. The pain self-efficacy questionnaire: taking pain into account. Eur J Pain. 2006;11:153–63.CrossRefPubMed
41.
Turk DC. The potential of treatment matching for subgroups of patients with chronic pain: lumping versus splitting. Clin J Pain. 2005;21(1):44–55.CrossRefPubMed
42.
Khanna D, Khanna PP. A 54-year old woman with pain and stiffness of hands and tendon friction rubs. In: Silver RM, Denton CP, editors. Case studies in systemic sclerosis. New York: Springer; 2011. p. 267–72.CrossRef
43.
Shah AA, Wigley FM. My approach to the treatment of scleroderma. Mayo Clin Proc. 2013;88(4):377–93.CrossRefPubMed
44.
Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43(1):56–62.CrossRefPubMed
45.
Motegi S, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, et al. Efficacy of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol. 2017;97(7):843–50.CrossRefPubMed
46.
Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69(8):1661–9.CrossRefPubMedPubMedCentral
47.
Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Am. 2014;39(8):876–80.CrossRef
48.
DeLea SL, Chavez-Chiang NR, Poole JL, et al. Sonographically guided hydrodissection and corticosteroid injection for scleroderma hand. Clin Rheumatol. 2011;30(6):805–13.CrossRefPubMedPubMedCentral
49.
Sencan S, Güler E, Cüce I, Erol K. Fluoroscopy-guided intra-articular steroid injection for sternoclavicular joint arthritis secondary to limited cutaneous systemic sclerosis: a case report. Korean J Pain. 2017;30(1):59–61.CrossRefPubMed
50.
Lundborg CN, Nitescu P V, Appelgren LK, Curelaru ID. Progressive systemic sclerosis: intrathecal pain management. Reg Anesth Pain Med. 24(1):89–93.
51.
Ingegnoli F, Ughi N, Crotti C. Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports. Clin Interv Aging. 2016;11:307.CrossRefPubMedPubMedCentral
52.
Giuggioli D, Manfredi A, Colaci M, Ferri C. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers. Pain Med. 2010;11(10):1500–3.CrossRefPubMed
53.
Dowell D, Haegerich TM, Chou RCDC. Guideline for prescribing opioids for chronic pain—United States, 2016. Morb Mortal Wkly Rep. 2016;65(1):1–49.CrossRef
54.
Chiou G, Crowe C, Suarez P, Chung L, Curtin C, Chang J. Digital sympathectomy in patients with scleroderma. Ann Plast Surg. 2015;75(6):637–43.CrossRefPubMed
55.
Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol. 2005;32(4):642–8.PubMed
56.
Momeni A, Sorice SC, Valenzuela A, Fiorentino DF, Chung L, Chang J. Surgical treatment of systemic sclerosis-is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery. 2015;35(6):441–6.CrossRefPubMed
57.
Tomaino MM, Goitz RJ, Medsger TA. Surgery for ischemic pain and Raynaud’s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery. 2001;21(3):75–9.CrossRefPubMed
58.
Francaviglia N, Silvestro C, Maiello M, Bragazzi R, Bernucci C. Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud’s syndrome. Br J Neurosurg. 1994;8(5):567–71.CrossRefPubMed
59.
Provenzano DA, Nicholson L, Jarzabek G, Lutton E, Catalane DB, Mackin E. Spinal cord stimulation utilization to treat the microcirculatory vascular insufficiency and ulcers associated with scleroderma: a case report and review of the literature. Pain Med. 2011;12(9):1331–5.CrossRefPubMed
60.
Fitzcharles M-A, Almahrezi A, Shir Y. Pain: understanding and challenges for the rheumatologist. Arthritis Rheum. 2005;52(12):3685–92.CrossRefPubMed
61.
Iversen MD, Brawerman M, Iversen CN. Recommendations and the state of the evidence for physical activity interventions for adults with rheumatoid arthritis: 2007 to present. Int J Clin Rheumtol. 2012;7(5):489–503.CrossRefPubMedPubMedCentral
62.
Veldhuijzen van Zanten JJCS, Rouse PC, Hale ED, et al. Perceived barriers, facilitators and benefits for regular physical activity and exercise in patients with rheumatoid arthritis: a review of the literature. Sport Med. 2015;45(10):1401–12.CrossRef
63.
Sharif K, Watad A, Bragazzi NL, Lichtbroun M, Amital H, Shoenfeld Y. Physical activity and autoimmune diseases: get moving and manage the disease. Autoimmun Rev. 2018;17(1):53–72.CrossRefPubMed
64.
Azar M, Rice DB, Kwakkenbos L, et al. Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. Disabil Rehabil 2017:1–7.
65.
Liem SIE, Meessen JMTA, Wolterbeek R, Ajmone Marsan N, Ninaber MK, Vliet Vlieland TPM, et al. Physical activity in patients with systemic sclerosis. Rheumatol Int. 2018;38(3):443–53.CrossRefPubMed
66.
Cuomo G, Santoriello C, Polverino F, Ruocco L, Valentini G, Polverino M. Impaired exercise performance in systemic sclerosis and its clinical correlations. Scand J Rheumatol. 2010;39(4):330–5.CrossRefPubMed
67.
Oliveira NC, dos Santos Sabbag LM, de Sá Pinto AL, Borges CL, Lima FR. Aerobic exercise is safe and effective in systemic sclerosis. Int J Sports Med. 2009;30(10):728–32.CrossRefPubMed
68.
Pinto ALS, Lia N, Oliveira C, et al. Efficacy and safety of concurrent training in systemic sclerosis. J Strength Cond Res. 2011;25(5):1423–8.CrossRefPubMed
69.
Maddali-Bongi S, Del Rosso A. Systemic sclerosis: rehabilitation as a tool to cope with disability. Clin Exp Rheumatol. 2016;34(5):162–9.PubMed
70.
Maddali Bongi S, Del Rosso A, Galluccio F, et al. Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol. 2009;27(3):44–50.PubMed
71.
Mugii N, Hamaguchi Y, Maddali-Bongi S. Clinical significance and usefulness of rehabilitation for systemic sclerosis. J Scleroderma Relat Disord. 2018;3(1):71–80.CrossRefPubMedPubMedCentral
72.
Poole JL. Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol. 2010;22(2):205–12.CrossRefPubMed
73.
Murphy SL, Barber M, Homer K, Dodge C, Cutter G, Khanna D. Occupational therapy treatment to improve upper extremity function in individuals with early systemic sclerosis: a pilot study. Arthritis Care Res. 2018; https://​doi.​org/​10.​1002/​acr.​23522.
74.
• Rannou F, Boutron I, Mouthon L, Sanchez K, Tiffreau V, Hachulla E, et al. Personalized physical therapy versus usual care for patients with systemic sclerosis: a randomized controlled trial. Arthritis Care Res. 2017;69(7):1050–9. Presents data from a recent randomized trial of physical therapy for SSc pain treatment that may serve as a model for randomized trials evaluating other treatments.
75.
Daste C, Rannou F, Mouthon L, Sanchez K, Roren A, Tiffreau V, et al. Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: a secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. Semin Arthritis Rheum. 2018; https://​doi.​org/​10.​1016/​J.​SEMARTHRIT.​2018.​03.​013.
76.
Parisi S, Celletti C, Scarati M, Priora M, Laganà A, Peroni CL, et al. Neuromuscular taping enhances hand function in patients with systemic sclerosis: a pilot study. Clin Ter. 2017;168(6):e371–5.PubMed
77.
Pfizenmaier DH, Kavros SJ, Liedl DA, Cooper LT. Use of intermittent pneumatic compression for treatment of upper extremity vascular ulcers. Angiology. 2005;56(4):417–22.CrossRefPubMed
78.
• Poole JL, Skipper B, Mendelson C. Evaluation of a mail-delivered, print-format, self-management program for persons with systemic sclerosis. Clin Rheumatol. 2013;32(9):1393–8. Presents data from a pre- and post-test designed study of a self-management program for SSc pain treatment that may serve as a model for randomized trials evaluating other treatments.
79.
Mancuso T, Janet Poole L. The effect of paraffin and exercise on hand function in persons with scleroderma: a series of single case studies. J Hand Ther. 2009;22(1):71–8.CrossRefPubMed
80.
Sandqvist G, Åkesson A, Eklund M. Evaluation of paraffin bath treatment in patients with systemic sclerosis. Disabil Rehabil. 2009;26(16):981–7.CrossRef
81.
Maddali Bongi S, Del Rosso A, Passalacqua M, Miccio S, Cerinic MM. Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase. Arthritis Care Res. 2011;63(8):1134–41.CrossRef
82.
Young A, Khanna D. Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. Curr Opin Rheumatol. 2015;27(3):241–8.CrossRefPubMedPubMedCentral
83.
Poole JL, Mendelson C, Skipper B, Khanna D. Taking charge of systemic sclerosis: a pilot study to assess the effectiveness of an Internet self-management program. Arthritis Care Res. 2014;66(5):778–82.CrossRef
84.
Landim SF, Bertolo MB, Marcatto de Abreu MF, del Rio AP, Mazon CC, Marques-Neto JF, et al. The evaluation of a home-based program for hands in patients with systemic sclerosis. J Hand Ther. 2017; https://​doi.​org/​10.​1016/​J.​JHT.​2017.​10.​013.
85.
•• Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014;69(3):22–9. Reviews the literature on psychotherapeutic interventions for pain.
86.
Veehof MM, Oskam M-J, Schreurs KMG, Bohlmeijer ET. Acceptance-based interventions for the treatment of chronic pain: a systematic review and meta-analysis. Pain. 2011;152(3):533–42.CrossRefPubMed
87.
McCracken LM, Vowles KE. Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol. 2014;69(2):178–87.CrossRefPubMed
88.
Keefe FJ, Somers TJ. Psychological approaches to understanding and treating arthritis pain. Nat Rev Rheumatol. 2010;6(4):210–6.CrossRefPubMed
89.
Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin N Am. 2003;29(2):427–39.CrossRef
90.
•• Thombs BD, van Lankveld W, Bassel M, Baron M, Buzza R, Haslam S, et al. Psychological health and well-being in systemic sclerosis: state of the science and consensus research agenda. Arthritis Care Res. 2010;62(8):1181–9. Reviews the literature on SSc pain and describes research agenda for assessment and treatment.
91.
Center for Connected Health Policy. What is telehealth? http://​www.​cchpca.​org/​what-is-telehealth%0A.
92.
Buenaver LF, McGuire L, Haythornthwaite JA. Cognitive-behavioral self-help for chronic pain. J Clin Psychol. 2006;62(11):1389–96.CrossRefPubMed
93.
Greco CM, Rudy TE, Manzi S. Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum. 2004;51(4):625–34.CrossRefPubMed
94.
Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, Coín MA, Robles-Ortega H, Hidalgo-Tenorio C, et al. Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom. 2010;79(2):107–15.CrossRefPubMed
95.
Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finan P, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76(3):408–21.CrossRefPubMed
96.
Sharpe L. Psychosocial management of chronic pain in patients with rheumatoid arthritis: challenges and solutions. J Pain Res. 2016;9:137–46.CrossRefPubMedPubMedCentral
97.
Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: the process and practice of mindful change. 2nd ed. New York: Guilford; 2012.
98.
Davis MC, Zautra AJ, Wolf LD, Tennen H, Yeung EW. Mindfulness and cognitive-behavioral interventions for chronic pain: differential effects on daily pain reactivity and stress reactivity. J Consult Clin Psychol. 2015;83(1):24–35.CrossRefPubMed
99.
Sporbeck B, Mathiske-Schmidt K, Jahr S, Huscher D, Becker M, Riemekasten G, et al. Effect of biofeedback and deep oscillation on Raynaud’s phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int. 2012;32(5):1469–73.CrossRefPubMed
100.
Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud’s phenomenon in scleroderma. J Behav Med. 1984;7(4):343–53.CrossRefPubMed
101.
Macfarlane GJ, Paudyal P, Doherty M, Ernst E, Lewith G, MacPherson H, et al. A systematic review of evidence for the effectiveness of practitioner-based complementary and alternative therapies in the management of rheumatic diseases: osteoarthritis. Rheumatology. 2012;51(12):2224–33.CrossRefPubMed
102.
Hall A, Richmond H, Copsey B, Hansen Z, Williamson E, Jones G, et al. Physiotherapist-delivered cognitive-behavioural interventions are effective for low back pain, but can they be replicated in clinical practice? A systematic review. Disabil Rehabil. 2018;40(1):1–9.CrossRefPubMed